Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotechnology pioneer advancing DARPin therapeutics for oncology and radiopharmaceutical applications. This page provides investors and industry observers with official company announcements, clinical trial milestones, and strategic partnership updates.
Access the latest developments in MOLN's Radio-DARPin Therapy platform, Switch-DARPin candidates, and ophthalmology programs. Our curated news collection enables efficient tracking of regulatory filings, preclinical data disclosures, and financial results without promotional commentary.
Key content categories include clinical trial progress, collaborative research updates with partners like Orano Med, and technology platform innovations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for centralized access to Molecular Partners' verified announcements. For comprehensive analysis of MOLN stock performance, visit Stock Titan's dedicated market data section.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) released its financial results for 2021, noting a total revenue of CHF 9.8 million and a net loss of CHF 63.8 million. The company received CHF 150 million from Novartis following positive Phase 2 results for ensovibep, a DARPin therapeutic for COVID-19. Ensovibep has FDA Fast Track designation, with plans for global Phase 3 trials. Molecular Partners maintains strong financial health, projecting cash runway into 2025. The company aims to broaden its pipeline, including oncology and virology programs, while preparing for key regulatory submissions.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm, announced CEO Patrick Amstutz's participation in two investor events in March 2022. Key dates include the Credit Suisse London Global Healthcare Conference on March 1-2, and a Fireside chat at the Cowen Health Care Conference on March 9. Additionally, the FY 2021 annual report will be published on March 15, followed by an investor conference call on March 16. Webcasted presentations will be accessible via the company's website.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that CEO Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation is scheduled for February 16, 2022, at 9:20 am ET. This clinical-stage biotech company specializes in developing DARPin therapeutics, a novel class of custom-built protein drugs aimed at addressing healthcare challenges. Their work spans infectious disease, oncology, and ophthalmology, with partnerships among leading pharmaceutical companies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that its partner Novartis requested Emergency Use Authorization (EUA) from the U.S. FDA for ensovibep, a DARPin antiviral therapeutic candidate aimed at treating COVID-19. This request builds on positive Phase 2 trial results from the EMPATHY study involving 407 symptomatic patients infected with SARS-CoV-2. Ensovibep is designed to inhibit the virus's entry into cells by targeting the spike protein, showing potential advantages in treating COVID-19.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has partnered with Novartis, granting global rights to ensovibep, an antiviral treatment for COVID-19. Novartis will lead its development and commercialization. The agreement includes a CHF 150 million milestone payment to Molecular Partners and a 22% royalty on sales in relevant territories. This collaboration aims to accelerate ensovibep's availability via expedited regulatory processes. The company's cash reserves are projected to last into 2025, strengthened by this agreement.
BVF Partners L.P. has acquired shares from Essex Woodlands Health Ventures Funds, increasing its stake in Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) to 12.21%. The transaction, effective January 10, 2022, saw Essex Woodlands drop below the 3% threshold. The CEO, Patrick Amstutz, expressed gratitude for Essex's past support and optimism about the recent clinical success of their COVID-19 drug developed with Novartis. BVF's Mark Lampert highlighted the potential of their drug, ensovibep, in combatting current and future SARS-CoV-2 variants.
Molecular Partners AG announced the successful results from the EMPATHY Part A study, focusing on its DARPin antiviral therapeutic candidate, ensovibep, for treating acute COVID-19. The primary endpoint of viral load reduction was met, while the secondary endpoint showed a 78% reduction in hospitalization and ER visits across treatment arms. No deaths occurred in patients receiving ensovibep. Upon in-licensing, Molecular Partners will receive a 150M CHF milestone payment and a 22% royalty on sales. The therapy maintains effectiveness against SARS-CoV-2 variants, including Omicron.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that CEO Patrick Amstutz will present at key healthcare investor events in January 2022. Key conferences include the H.C. Wainwright BioConnect 2022 on January 10, the JP Morgan 40th Annual Virtual Healthcare Conference on January 12, and the Baader Helvea Swiss Equities Conference on the same day. Additionally, Amstutz will participate in the Octavian Seminar 2022 on January 14. All presentations will be available for viewing on the Molecular Partners website.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) hosted a virtual Oncology R&D Day on December 15, 2021, covering advancements in their therapeutic pipeline.
Key updates included:
- 2022 clinical strategy and corporate outlook by CEO Patrick Amstutz.
- Status of Abicipar, an anti-VEGF treatment update by COO Michael Stumpp.
- Technological advancements in DARPin therapeutics.
- Emerging treatments for AML presented by university professors.
The event highlighted continued progress despite COVID-19, including a new collaboration with Novartis.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced a collaboration with Novartis to develop DARPin-conjugated radioligand therapies (DARPin-RLTs) aimed at cancer treatment. Under the deal, Novartis will pay $20 million upfront, with potential milestone payments totaling up to $560 million and low double-digit royalties on sales. This collaboration combines Molecular Partners’ expertise in DARPin technology with Novartis’ capabilities in radioligand therapy, promising targeted delivery of radiation to tumor cells.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
